243 related articles for article (PubMed ID: 8547651)
21. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome.
Warzocha K; Ribeiro P; Bienvenu J; Roy P; Charlot C; Rigal D; Coiffier B; Salles G
Blood; 1998 May; 91(10):3574-81. PubMed ID: 9572991
[TBL] [Abstract][Full Text] [Related]
23. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.
Haioun C; Lepage E; Gisselbrecht C; Bastion Y; Coiffier B; Brice P; Bosly A; Dupriez B; Nouvel C; Tilly H; Lederlin P; Biron P; Brière J; Gaulard P; Reyes F
J Clin Oncol; 1997 Mar; 15(3):1131-7. PubMed ID: 9060555
[TBL] [Abstract][Full Text] [Related]
24. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
Wendum D; Sebban C; Gaulard P; Coiffier B; Tilly H; Cazals D; Boehn A; Casasnovas RO; Bouabdallah R; Jaubert J; Ferrant A; Diebold J; de Mascarel A; Gisselbrecht C
J Clin Oncol; 1997 Apr; 15(4):1654-63. PubMed ID: 9193366
[TBL] [Abstract][Full Text] [Related]
25. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
[TBL] [Abstract][Full Text] [Related]
26. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
Bastion Y; Blay JY; Divine M; Brice P; Bordessoule D; Sebban C; Blanc M; Tilly H; Lederlin P; Deconinck E; Salles B; Dumontet C; Brière J; Coiffier B
J Clin Oncol; 1997 Aug; 15(8):2945-53. PubMed ID: 9256139
[TBL] [Abstract][Full Text] [Related]
27. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study.
Cazals-Hatem D; Lepage E; Brice P; Ferrant A; d'Agay MF; Baumelou E; Brière J; Blanc M; Gaulard P; Biron P; Schlaifer D; Diebold J; Audouin J
Am J Surg Pathol; 1996 Jul; 20(7):877-88. PubMed ID: 8669537
[TBL] [Abstract][Full Text] [Related]
28. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Mounier N; Briere J; Gisselbrecht C; Emile JF; Lederlin P; Sebban C; Berger F; Bosly A; Morel P; Tilly H; Bouabdallah R; Reyes F; Gaulard P; Coiffier B
Blood; 2003 Jun; 101(11):4279-84. PubMed ID: 12576316
[TBL] [Abstract][Full Text] [Related]
29. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
30. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
[TBL] [Abstract][Full Text] [Related]
32. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
[TBL] [Abstract][Full Text] [Related]
33. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma.
Gascoyne RD; Krajewska M; Krajewski S; Connors JM; Reed JC
Blood; 1997 Oct; 90(8):3173-8. PubMed ID: 9376600
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Gisselbrecht C; Gaulard P; Lepage E; Coiffier B; Brière J; Haioun C; Cazals-Hatem D; Bosly A; Xerri L; Tilly H; Berger F; Bouhabdallah R; Diebold J
Blood; 1998 Jul; 92(1):76-82. PubMed ID: 9639502
[TBL] [Abstract][Full Text] [Related]
36. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
37. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
38. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
39. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
40. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
